Introduction
Tumor cells remaining after chemotherapy may be intrinsically resistant to chemotherapy and represent the disease, which may later recur. There has, therefore, been an increasing interest in identifying genes/pathways enriched or depleted in residual tumors, which may eventually be targetable and used for selection of patients to include in clinical trials on new drugs. Evidence for the clinical importance of these features may be obtained by establishing their long-term prognostic value, but this has been addressed infrequently, and many reports have focused on triple-negative breast cancers (TNBC) patients only, for whom no targetable treatment option is currently available.
Neoadjuvant chemotherapy (NAC) offers the possibility of in vivo assessments of treatment response and increases the rates of breast conserving surgery. It has increased in breast cancer, as it has been proven equally effective as adjuvant treatment. Biologic studies of residual disease after chemotherapy are much more straightforward in NAC than in metastatic disease because of ready access to biopsy tissue.
With NAC approximately 10% to 15% of estrogen receptor (ER)-positive and 30% of HER2-negative and TNBC achieve a pathologic complete response (pCR), which is now an FDAapproved surrogate end-point for good long-term outcome and may be used for supporting accelerated approval of new drugs (1). For the majority of patients who do not achieve a pCR, the outcome is, however, more heterogeneous and difficult to predict (2) . The residual cancer burden (RCB) is one validated long-term outcome predictive model (3) . High residual Ki67 in the surgical sample, alone (4), or combined with RCB (Residual Proliferative Cancer Burden, RPCB; ref. 5 ) has also been promising in identifying patients with a poorer outcome who might be considered for inclusion in clinical studies with further treatment after surgery to improve outcome.
The aims of the present study were to determine whether there was clinical evidence for the involvement of one or more from a panel of candidate genes in chemotherapy resistance. We determined this by studies of changes of gene expression on treatment, as well as the impact on long-term prognosis in a cohort, including both ER þ and ER À patients treated with NAC.
The genes were chosen from literature review on the basis of their being identified as (i) possible prognostic factors in residual disease at protein (4, (6) (7) (8) (9) (10) or mRNA level (11) , (ii) as significantly up-or downregulated, but of unknown prognostic value in residual disease (12) (13) (14) (15) (16) (17) (18) (19) (20) , (iii) as predictive of chemotherapy resistance (6, 11, 16, 19, (21) (22) (23) (24) (25) (26) (27) (28) (29) , and/or (iv) identified as possible prognostic factors over several previous datasets (26, (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) . In addition to the previously established prognostic factors ESR1 and ERBB2, the genes were also chosen to represent different pathways and biological processes of known implication in tumor progression or response to therapy, such as stemcellness (ALDH1A1, CD44, and STAT3), proliferation (TOP2A, MKI67, and AURKA), apoptosis (BCL2, BCL2L1, and PAWR), immunologic response (CD3D, CXCL13, and STAT1), epithelial-to-mesenchymal transition (EMT; SNAI1, SNAI2, SOX9, and TWIST), stromal activation (DECORIN, SPARC, and PLAU), energy metabolism (ACACB and LDHB), and ERK/Ras activation (DUSP4). Changes in gene expression in response to NAC, as well as the long-term prognostic value of gene expression in residual disease in all patients, and in subgroups based on ER and HER2 status were chosen as endpoints.
Materials and Methods

Patients
The 126 patients in the present study were derived from a previously described cohort from a study on the prognostic value of Ki67 in addition to RCB in residual disease after NAC (5) . That study included 220 T1-4, N0/þ, M0 patients who between 2001 and 2010 received NAC followed by surgery at the Royal Marsden Hospital. Patients were excluded from further analysis due to (i) pCR (n ¼ 49), (ii) insufficient tumor due to low cellularity (n ¼ 31), (iii) unavailability of tumor blocks (n ¼ 11), or (iv) insufficient RNA yield (n ¼ 3), see REMARK flow-chart, Supplementary Fig. S1 . Of the remaining 126 patients, 56 also had a paired pre-surgical biopsy available with sufficient tumor available for RNA extraction, taken at the time of diagnosis before start of chemotherapy. Details on treatments and baseline patient and tumor characteristics can be found in Table 1 . The median follow-up for the end-point time to recurrence (TTR) for patients alive and free from relapse at the last review of the patients' records was 4.1 years.
Methods
Pathologic assessment of the biopsies and residual tumor tissue Pre-and post-treatment Ki67 was determined by the MIB-1 antibody (DAKO, K5001) on formalin-fixed paraffin-embedded (FFPE) tissue by counting all, but no less than 200, invasive tumor cells in 5 high-power fields (Â40 objective) representative of the tumor heterogeneity and recording the percentage of positively stained cells (42) . CD3D in residual tumors tissue was determined by the use of the rabbit polyclonal CD3D antibody (Proteintech). CD3D-positive lymphocytes were assessed semiquantitatively in relation to tumor size and scored as "low to moderate" and "high."
Tissue macrodissection and mRNA extraction
To identify samples and areas of interest for mRNA extraction, a 4-mm section from the residual surgical FFPE block was stained with hematoxylin and eosin (H&E), and areas with !40% invasive tumor cells were outlined. One to six consecutive 8-mm sections were cut on to slides, baked overnight at 37 degrees, and stained with a 1% solution of Nuclear Fast Red (NFR; Sigma). The areas marked out on the H&E were identified on the NFR-stained sections, needle macrodissected, and collected into an RNAse-free tube. Nucleic acid purification was performed using RecoverAll kit (Ambion) according to the manufacturer's instructions, quantified by the QubitRNA BR Assay Kit (both Life Technologies) and stored at À20 C.
Gene-expression profiles: NanoString nCounter analysis and data processing Expression of the 24 genes of interest (Supplementary Table  S1 ) was assessed as part of a panel of 82 genes in which the other 58 were assessed for separate reasons and not considered further in this study other than for the purposes of analytical normalization. Fifty to 100 ng total RNA was analyzed using a NanoString nCounter. Expression data were normalized with custom scripts in R. Background correction was done by subtracting the mean of the 8 negative control probes. Expression values were normalized with the three housekeeping genes that had the highest correlation amongst the housekeeping genes (ACTB, MPRL19, and TFRC). Expression values were log 2 transformed and standardized within each sample. The 24 genes in the present study were detected in >80% of the samples. For residual samples, expression values were gene centered using a subpopulation of 86 samples with balanced ER þ /ER À distribution.
Statistical analysis
The primary analysis was to evaluate changes in gene expression, and the secondary analysis was to investigate the
Translational Relevance
Neoadjuvant chemotherapy offers estimation of treatment response as well as assessment of long term prognosis. In this study, expression of 24 genes representing key biologic processes was quantified in 126 residual tumors and 56 paired biopsies. Chemotherapy induced significant upor downregulation of most genes, and in residual disease 14 genes representing proliferation, stromal activation, metabolism, apoptosis, stemcellness, and Ras-ERK activation predicted prognosis, suggesting a biologic role in chemoresistant disease. 
Results
Patient and tumor characteristics
During follow-up, which due to non-proportional hazards was restricted to 5 years, 46 patients were diagnosed with local, regional, and/or distant recurrences and 32 patients died. At 5 years the overall survival was 75% [95% confidence interval (CI), 67%-83%]. Detailed characteristics of the patients are presented in Table 1 . Median age at diagnosis was 51 years, and 47% were node-positive at diagnosis. Sixty-six percent of cases were ER þ , 52% PgR
The majority of HER2 þ cases received trastuzumab (11/15) and 47% received this neoadjuvantly. Nearly all patients received anthracyline-containing chemotherapy (98%) and the majority (64%) also received neoadjuvant taxanes. According to local practice at the time, before the routine use of neoadjvant taxanes, a proportion of patients treated with neoadjuvant anthracyclines went on to receive adjuvant taxane chemotherapy following surgery (14%). Forty-eight percent of the patients were treated with breast-conserving surgery.
Correlations
Details of the gene set selected can be found in Supplementary Table S1 . A correlation matrix of associations between the 24 genes and the IHC assessments of presurgical ER, HER2, and residual Ki67 can be found as Supplementary Fig. S2 . Residual IHC Ki67 was positively correlated with the expression of other proliferation genes and LDHB, and negatively correlated with IHC ER, ESR1, ACACB, ALDH1A1, BCL2, DECORIN, and TWIST, with the opposite correlation pattern for the same genes found for presurgical IHC ER.
Changes in gene expression following NAC
Of the 126 residual samples, there were 56 available presurgical biopsies, out of which 36 were ER þ /HER2 À , and 13 ER À
/HER2
À . In paired comparisons there was a significant dowregulation of all proliferation genes after chemotherapy (MKI67, TOP2A, and AURKA), as well as BCL2L1, PLAU, STAT1, and the stem cell markers CD44 and STAT3. The EMT genes SNAI1, SNAI2, SOX9, and TWIST, the apoptosis genes PAWR and BCL2, the Ras-ERK-associated DUSP4, the metabolism-related genes ACACB and LDHB, ALDH1A1, and the stromal genes DECORIN and SPARC, were all significantly upregulated (Table 2 ). There were no significant changes in the expression of ESR1, ERBB2, or the immune-related genes CD3D and CXCL13 ( Table 2 ). Seventeen of these 20 genes were similarly significantly up-or downregulated in the ER þ /HER2 À patients (see Table 2 ). However, in the ER À /HER2 group, only SNAI2 and STAT1 changed significantly after chemotherapy (data not shown).
Gene-expression patterns in residual disease
A heat map visualizing the gene-expression patterns in a dendrogram of the 24 genes in the 126 residual tumours was determined after unsupervised clustering is shown in Fig. 1 . The first cluster consists of mainly ER À , HER2
À tumors with high residual Ki67, and in this cluster of 41 tumors the majority of relapses can be found (n ¼ 27). The cluster is characterized by overexpression of proliferation genes (MKI67, AURKA, and TOP2A), and LDHB (indicating a glycolytic phenotype), the EMT genes SOX9 and SNAI1, and low expression of ESR1, ACACB (indicating an increase in fatty acid oxidation), BCL2, BCL2L1, the EMT genes TWIST and SNAI2, ALDH1A1, DUSP4 (indicating increased Ras-ERK activation), and DECORIN. In the other three clusters, the majority of tumours are ER-positive, have lower residual Ki67 levels, and fewer relapses. This is reflected in an expression pattern reverse to the first cluster with lower expression levels of proliferation genes, and higher expression levels of ESR1 and genes strongly associated to ESR1.
Relationship of gene expression in residual disease and prognosis: univariable analyses
In univariable analyses 14 genes representing proliferation (AURKA, MIK67, and TOP2A), stromal activation (DECORIN and PLAU), metabolism (ACACB and LDHB), apoptosis (BCL2 and BCL2L1), stemcellness (ALDH1A1), EMT (SNAI2 and TWIST), Ras-ERK activation (DUSP4), and ESR1 were significantly associated with TTR (Table 3 ). The strongest HRs were found for AURKA (HR, 5.2; 95% C,1.9-14; P ¼ 0.001), LDHB (HR, 4.1; 95% CI, 2.0-8.1; P < 0.0001), MIK67 (HR, 3.9; 95% CI, 2.3-6.7; P < 0.0001), DECORIN (HR, 0.28; 95% CI, 0.17-0.48; P < 0.0001), BCL2 (HR, 0.29; 95% CI, 0.17-0.49; P < 0.0001), and ACACB (HR, 0.32; 95% CI, 0.22-0.48; P < 0.0001; Table 3 ; Fig. 2A-F) . When dividing the gene expressions into tertiles, there were significant differences in 5-year TTR (log 1st tertile vs. 2ndþ3rd tertiles, log-rank test) for ACACB (P < 0.0001), ALDH1A1 (P ¼ 0.00018), BCL2 (P < 0.0001), DECORIN (P < 0.0001), ESR1 (P < 0.0001), and MIK67 (highest 1st tertile vs. 2ndþ3rd tertiles, P < 0.0001), Fig. 2A-F , but also AURKA, BCL2L1, CD44, DUSP4, ERBB2, LDHB, TOP2A, and TWIST ( Supplementary Fig. S3A-S3X) . Notably, there was a clear threshold effect for the expression levels of ESR1 and the proliferation genes, especially MIKI67. A similar pattern with threshold effects could be seen only for genes which were strongly correlated to either ESR1 or MIKI67 (ACACB, ALDH1A1, AURKA, TOP2A, BCL2, DECORIN, DUSP4, LDHB, and TWIST), with no such effect found for genes with a weaker correlation to either MIKI67 or ESR1.
Even though events were few in the subgroups, analyses of the prognostic value of the individual genes were performed to identify associations within subgroups defined by ER and HER2 status. Given that only 15 patients were HER2 positive, the exploratory analyses were restricted to the Relationship between gene expression in residual disease and prognosis: multivariable analyses First, a fixed multivariable model incorporating clinical factors of previously known prognostic value (ER, PgR, and HER2) was adjusted for one gene at a time for the 118 patients who had data available for all three clinical factors. In this model, MIK67 (HR, 3.4; 95% CI, 1.6-7.3; P ¼ 0.002), ACACB (HR, 0.37; 95% CI, 0.20-0.70; P ¼ 0.002), TOP2A (HR, 2.2; 95% CI, 1.2-4.2; P ¼ 0.018) and CD3D (HR, 0.56; 95% CI, 0.31-0.92; P ¼ 0.024) added independent prognostic value ( Table 4) . As an exploratory analysis, residual IHC Ki67 was added to form an IHC4 model, and the findings were similar, with added prognostic information found for ACACB but also a retained prognostic value of MIK67 (Supplementary Table S2 ).
For identifying genes in residual disease predictive of long-term prognosis in multivariable models in (i) all patients (n ¼ 126), as well as in the largest subgroup, (ii) the ER þ /HER2
À patients (n ¼ 78), the elastic net Cox regression was used. In all patients, six genes with a non-zero regression coefficient were selected: ACACB, CD3D, DECORIN, ESR1, MIK67, and PLAU, predictive of outcome with a c-index of 0.79 in a multivariable Cox Proportional Hazards (CoxPH) model. The 6-gene model added prognostic value independent of the clinical base-line factors ER, PgR, and HER2 (P ¼ 0.0067), whereas ER, PgR, and HER2 did not add significant prognostic value in a Cox regression model that included the 6-gene model (c-index estimation 0.79). In the ER þ /HER2 À patients, 4 genes with a non-zero regression coefficient were selected; ACACB, ERBB2, MIK67, and PAWR predictive of TTR with a c-index of 0.71 in a multivariable Cox regression model (data not shown). A statistically significant association was found between protein and mRNA expression of CD3D in the ER À /HER2 À subset (n ¼ 32, P ¼ 0.008) supporting the possibility of a functional association, Supplementary  Fig. S4 . 
Discussion
The characteristics of the tumor cells surviving NAC are of major interest as they enable the study of changes in biologic processes in response to chemotherapy and chemotherapy resistance, may represent the features of disease which may later recur, and are likely to provide information relevant to the longterm prognosis of patients with residual disease. Today, as increasing numbers of patients are offered NAC, new prognosticators correctly identifying patients with an inferior prognosis in need of additional therapy after NAC are much needed. In this study, we therefore sought to examine genes in residual disease and paired biopsies, representing different biologic pathways with previously published implications for breast cancer prognosis or resistance to chemotherapy. Their relationship with long-term prognosis was examined to provide further support for their clinical relevance and to assess their potential for incorporation as a predictor of risk of recurrence. The prognostic value in subgroups based on ER and HER2 status and multivariable models were considered secondary endpoints.
NAC affected the majority of the selected genes, with significant up-or downregulation of the expression levels of 12 and 8 genes, respectively. Only ESR1 and ERBB2, which are the major determinants of intrinsic subgroups, and CD3D, and CXCL13 remained unchanged. As expected, the proliferation genes were all downregulated, consistent with proliferating cells being more responsive to chemotherapy. However, tumors with high residual proliferation rates had a significantly worse long-term prognosis, with AURKA, TOP2A, and MKI67 all conferring prognostic information, validating previous results of the strong negative impact of high residual Ki67 alone (4) or as part of the RCB (5). Notably, there was an apparent threshold effect for MIKI67, with a probability of remaining relapse-free at 5-years of 37%, compared with 84% for the highest and lowest tertiles, respectively. MKI67 and TOP2A also added prognostic value independent of clinical ER, PgR, and HER2 status in multivariable models predictive of long-term outcome in all patients, as well as in ER þ /HER2 À patients. Interestingly, IHC Ki67 and MIK67 were strongly correlated, but in an exploratory fixed model incorporating clinical ER, PgR, HER2, and IHC Ki67, MKI67 still added independent prognostic value to this model. Thus, although highly proliferative cells and tumors are more sensitive to chemotherapy, the persistence of highly proliferative cells in the face of chemotherapy is associated with very poor outcome. The stroma-associated genes DECORIN and SPARC were significantly upregulated after NAC, and high residual DEC-ORIN was a strong predictor of improved outcome. The positive prognostic value of DECORIN found here in residual disease, as well as previously in primary ER disease (30) , could be explained by in vitro studies in which the proteoglycan DECORIN acts as a potent inhibitor of proliferation by interacting with TGFb, EGFR, insulin-like growth factor receptor, and low density lipoprotein receptor-related protein (43) . Moreover, DECORIN was chosen to represent an activated stroma in the Farmer metagene, with high levels predictive of resistance to chemotherapy in ER À disease (23) . High levels of PLAU and the corresponding protein u-PA, needed for breakdown of the extracellular matrix, have been associated with prediction of benefit of adjuvant chemotherapy and worse outcome (23, 44) , and in the present dataset a similar trend with a better outcome for low levels of PLAU was found. None of the stromal genes retained independent prognostic value in the multivariable models, which may be due to the strong correlation found with ER status. Genes associated with reprogramming of energy metabolism, one of the hallmarks of cancer, were represented by LDBH and ACACB; both were upregulated after NAC and significantly associated with survival. High residual levels of LDHB, expressed in the microenvironment and suggestive of a glycolytic phenotype, which bypasses oxidative phosphorylation, were associated with a poor outcome (6) . This supports previous data in which high levels has been associated with a better response to NAC and impaired survival in residual TNBC (6) . The Acetyl-CoA carboxylases (ACC) A and B, convert acetylCoA to malonyl-CoA, a rate-limiting step in fatty acid synthesis. Where ACACA, localized in the cytosol, is mostly involved in fatty acid synthesis, high levels of ACACB, localized in the mitochondria, also regulate and inhibit fatty acid oxidation (45) , which would account for the favorable outcome of patients with high levels of ACACB found in the present study, where inhibition of fatty acid oxidation impairs the energy requirements of the tumor cells. ACACB was, as in previous findings (14) , enriched in residual disease irrespective of ER status. Even though there was a strong positive correlation between ACACB and ER status, with the exception of ER À
/HER2
À patients, ACACB added independent prognostic value in all multivariable models also including ER or ESR1 status.
Of the three apoptosis-related genes chosen, high-expression levels of BCL2, and to a lesser extent BCL2L1, was significantly associated with a better long-term outcome, as in earlier publications both in primary tumors (34) and residual tumors after NAC (8) . There was a significant upregulation of BCL2 and downregulation of BCL2L1 following NAC. Even though BCL2 is mainly antiapoptotic, it is through the antiproliferative (46) and proapaptotic functions especially evident at higher expression levels, which BCL2 also exhibits (47) , the positive prognostic value may emanate. Previous studies on the pro-apoptotic gene PAWR have found a negative prognostic value of low mRNA levels of PAWR in primary tumors, downregulation following NAC, but an unknown prognostic impact in residual disease (16) . In the present study, PAWR was upregulated in response to chemotherapy, but no significant univariable prognostic value could be found in all patients. However, there was a significant difference in the prognostic impact of PAWR in subgroups based on ER status, where low levels of the pro-apoptotic gene PAWR in residual disease was significantly predictive of an improved outcome in the ER À /HER2 À cohort only, with the reverse results found in ER þ /HER2 À tumors. This difference in prognostic impact based on ER status also corresponded to a significant term of interaction. TWIST, SNAI1, SNAI2, and SOX9, the four EMT genes, are thought to facilitate EMT mainly by repressing e-cadherin expression needed for cells to maintain cell-to-cell adhesion, and high protein levels have generally been associated with an impaired prognosis in primary disease (40, 41) . In the present study, the expression levels of all EMT genes were significantly upregulated after NAC in line with previous studies (14) ; however, the prognostic value of high residual expression of the genes differed.
Unexpectedly, high residual TWIST and SNAI2 was significantly associated with an improved outcome, whereas patients with low SNAI1 and SOX9 expression levels instead showed a nonsignificant trend toward improved survival (10, 15, 40) . Previous studies have only addressed the prognostic value of TWIST and SNAI2 in primary tumors, and there may be differences in profiling primary versus residual disease. An independent validation would, however, be needed to further elucidate the prognostic impact of TWIST and SNAI2 after NAC before definite conclusions can be drawn.
In the present dataset, of the stem cell markers CD44, STAT3, and ALDH1A1, generally associated with self-renewal and resistance to chemotherapy when expressed by epithelial cells in primary tumours, only high ALDH1A1, which was also significantly upregulated in response to NAC, conveyed independent prognostic value, and contrary to the expected, with high residual levels, indicating an improved outcome. This may, however, be consistent with findings in another study on residual tumors, where no prognostic significance or increase in expression of epithelial ALDH1 was found after NAC, however, high residual stromal expression of ALDH1 was associated with an improved outcome (9) . Moreover, even though ALDH1 is expressed at higher levels in chemotherapy resistant cancer stem cells (48) , it also involved in the synthesis of retinoic acid, which has an antiproliferative effect by facilitating the action of other breast cancer cell growth inhibitors (49) .
An increase in immunologic response, represented by CD3D, CXCL13, and STAT1 has been associated with improved survival in several publications (50) . In this dataset, CD3D, as part of immunologic signatures proven predictive of NAC response (19) and prognosis (51) , was the only immunologic marker that displayed prognostic value in ER À /HER2 À patients, in the clinical multivariable model adjusting for clinical ER, PgR, and HER2, and as part of the 6-gene-predictive multivariable model. This is consistent with findings in a recent publication in which high levels of tumor-infiltrating lymphocytes, which are significantly associated with CD3D expression (19) , in residual disease were associated with in improved outcome in TNBC (50) . We also found a significant statistical association between IHC CD3D and mRNA expression levels, supporting the possibility of a functional association. However, together with ESR1, ERBB2, NAC did not induce a significant change in either CXCL13 or CD3D expression. Finally, the MAPK phosphatase DUSP4, a negative regulator of the Ras-ERK pathway was significantly enriched in response to chemotherapy, with low levels of DUSP4 in residual disease associated with an impaired prognosis, in agreement with earlier studies on TNBC (11). Even so, there was no independent prognostic value of DUSP4 in any of the subgroups or in multivariable analyses. We chose not to conduct analyses of the MAPK pathway by measuring phosphorylated proteins because we have reported the catastrophic loss of immunohistochemical staining of p-AKT and p-ERK1/2 in routinely fixed breast cancer excisions (52) . Pre-analytic variables may also affect transcript analyses, but the inclusion of housekeeper genes helps cater for artefacts. Other studies have found that DUSP4 mRNA expression inversely correlated with a gene-expressionbased Ras-ERK pathway score in 230 primary breast cancers (11) , and in 633 breast tumors from The Cancer Genome Atlas we observed an inverse correlation with BRAF and DUSP4 mRNA expression (Supplementary Table S3 À patients. Notably, HER2 expression was significantly associated with risk of relapse even in the HER2 À cohort, with low rather than high expression associated with greater risk, consistent with our previous reports on the ABC and ATAC adjutant trials (54, 55) . This may be partly due to a direct relationship between ER and HER2 expression in the HER2 À group (with higher ER expression being linked to better prognosis) or to loss of that locus on chromosome 17 in genetically unstable, poorer prognosis tumors. Similarly, in a fixed multivariable IHC3 model, including ER, PgR, and HER2, ACACB, CD3D, MKI67, and TOP2A provided independent prognostic value. Finally, a penalized Elastic net Cox regression analysis in all patients identified six genes, including ACACB, CD3D, DECORIN, ESR1, MKI67, and PLAU, which added significant prognostic value independent of clinical ER, PgR, and HER2. Conversely, clinical ER, PgR, and HER2 did not provide additional prognostic value when the 6-gene model was included in the Cox model. In the ERþ/HER2-patients, a 4-gene model (ACACB, ERBB2, MKI67, and PAWR) was equally predictive of time to relapse. An external validation study would be required to further determine the clinical validity of the gene models identified from this study. However, in this study, we took a stringent approach to reduce the likelihood of false discovery: We applied a FDR control approach to correct for multiple comparisons, and we set a threshold to control the expected proportion of falsely rejected null hypothesis to be less than 1% for the univariable analyses. For the multivariable analysis, the Elastic-net penalties regularization method was used for gene selection, a useful approach when dealing with highly correlated covariates.
In conclusion, by profiling presurgical biopsies and residual disease in patients who have not achieved a pCR after NAC, the present study identified 14 genes representing ER signaling (ESR1), proliferation (AURKA, MIK67, and TOP2A), stemcellness (ALDH1A1), EMT (TWIST and SNAI2), apoptosis (BCL2, BCL2L1, and PAWR), changes in energy metabolism (LDHB and ACACB), stromal processes (DECORIN and PLAU), immunologic response (CD3D), and Ras-ERK activation (DUSP4), which were all associated with an inferior prognosis. To determine their relative importance in individual patients and provide evidence for the targeting of these processes in chemoresistant disease would need larger numbers of patients. The multivariable gene models identified in all patients as well as in the largest subgroup, the ER þ /HER2
À patients, could if they are validated be used to identify patients who could be offered further treatment or inclusion in studies on new drugs to improve their prognosis.
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